Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients - CRISP

AIO-Studien-gGmbH0 个研究点目标入组 5,000 人开始时间: 2016年7月6日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients who meet all of the following criteria are eligible for the project:Histologically confirmed non-small cell lung cancer (NSCLC)
•2. Informed consent no later than four weeks after start of first-line treatment
•3. Age = 18 years
•4. Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
•5. Main project:
•- Stage IV, IIIC or stage IIIB (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
•- Systemic therapy
•In the main project it is strongly recommended that patients’ tumor samples are tested for EGFR mutation in exons 18-21, ALK rearrangement and ROS1 rearrangement as well as PD-L1 expression by a certified laboratory before the start of first-line treatment.
•6. Satellite Stage II/III:
•- Stage II, stage IIIA or stage IIIB (UICC8) if patient is eligible for curative surgery and/or radiochemotherapy
•- systemic (chemo)therapy and/or radiation therapy and/or surgery

发起方